Latest pharma feed

Decision: Medical devices given exceptional use authorisations

Ανάκληση της παρτίδας EM1425 του καλλυντικού προϊόντος NEPTUNE AFTER SHAVE

Ανάκληση της παρτίδας 333570 του συμπληρώματος διατροφής HEALTHAID HAEMOVIT, Liquid Gold Blackcurrant taste

Reunión del Comité de Medicamentos Veterinarios de abril de 2026

Decision: Orphan registered medicinal products

natco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26

natco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26

natco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fda

natco receives approval from central drug standard control organisation cdsco for semaglutide in india

natco pharma limited api unit in chennai receives establishment inspection report eir from u s fda

natco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290

natco announces launch of pomalidomide capsules generic of pomalyst in the u s market

natco announces launch of its everolimus tablets 1 mg generic of zortress

legal update regarding risdiplam

intimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2

disclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015

adcock ingram completes delisting from jse natco pharma acquires 35 75 stake

6203

Home page

Astellas Doses First Patient in Phase 3 Study of setidegrasib (ASP3082) for KRAS G12D-mutated Metastatic Pancreatic Ductal Adenocarcinoma

Managing Financial Risk at Site Level: Practical Strategies for Underfunded Studies

The Need for Clinical Research Sites to Transition to e-Regulatory Binders: Strategies, Pros, and Cons

Measuring Quality in the Age of AI: Why Regulatory Writing Needs a True Standard

Enhancing the Quality of Investigator-Initiated Trials Through Self-Study Modules

From Mapping Your Pathway to Traversing a Career

Empowering Research-Naïve PIs for Complex and Advanced Therapeutic Trials

The Cost of Turnover in Clinical Operations: What Leaders Can Actually Do About It

Using AI to Unlock New Opportunities in Clinical Data Recruitment and Talent Development

A Practical Guide to Patient-Centric Trials Using Net Treatment Benefit

The Recurring Conundrum of Diversity: Targeted Precision as an Economically Calculable Strategy

Transplanting Islet Cells with Piotr Witkowski, MD, PhD

In Vivo’s 2026 Rising Leaders

Guidance: Declaration of Helsinki and Clinical Trial Regulations alignment

Guidance: Archiving and retention of clinical trial records

SELLAS Life Sciences - Clinical Biopharmaceutical Company

Interfarma no HBR Summit Brasil: painel debate cuidado baseado em valor como eixo para inovação e sustentabilidade

Interfarma no HBR Summit Brasil: cuidado baseado em valor é caminho para mais eficiência e melhores desfechos em saúde

Update on Construction of New Plasma-Derived Therapies Manufacturing Facility in Juso, Osaka | Takeda Pharmaceuticals

20,000+ Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 countries | Takeda Pharmaceuticals

Takeda Announces Completion of Acquisition of Own Shares | Takeda Pharmaceuticals

GAMMAGARD LIQUID ERC Approved for Primary Immunodeficiency

Filing of Corporate Governance Report to the Tokyo Stock Exchange | Takeda Pharmaceuticals

Takeda Announces the Pricing Terms of the Previously Announced Cash Tender Offers for Certain Outstanding Notes | Takeda

Takeda Announces New Assignments of Directors

Statement on Inadvertent Abstract Disclosure for Oveporexton (TAK-861) by World Sleep Congress

Takeda Reports Third-Quarter FY2025 Results | Takeda Pharmaceuticals

Takeda Phase 3 Study Results in Pediatric Ulcerative Colitis

Rusfertides Phase 3 Trial for Polycythemia Vera at ASCO 2025

Takeda Presents Long-Term Data from ADVANCE-CIDP 3 Trial of HYQVIA

Takeda to Hold Third Quarter FY2022 Earnings Call on February 2

Takeda Receives Approval to Manufacture and Market Entyvio® Subcutaneous Injection in Japan for the Maintenance Treatment of Moderate to Severe Ulcerative Colitis

Notice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japan

ADZYNMA® Receives European Commission Approval as First Recombinant ADAMTS13 Therapy for cTTP

U.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older

Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor

Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary

FDA Accepts Takeda’s Entyvio BLA

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Nuevos proyecto de consulta para la opinión pública

Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics

Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.

Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress

Decision: Parallel import licences granted in 2026

Avacta CEO Christina Coughlin Named as One of In Vivo’s 2026 Rising Leaders

Medicines: Get integrated scientific advice from the MHRA and NICE

[ANZEN]MHLW Pharmaceuticals and Medical Devices Safety Information No.428 posted

[SHINSA]The information of New Drug Review with Electronic Data updated

Bausch Health's Dermatology Business, Ortho Dermatologics, Announces the Launch of Biafine®, an Iconic French Skincare Product, Through Convenient Online Ordering

Biotech Bulls & Breakthroughs podcast: The Future of Biomanufacturing with Michael Heltzen

Field Safety Notices: 6 to 10 April 2026

Repenser la santé depuis les territoires : le signal venu de Dunkerque

Decision: Triheptanoin in the treatment of long-chain fatty acid oxidation disorders (LC-FAOD)

NervGen Pharma to Participate in the H.C. Wainwright “HCW@Home” Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference

El Informe Anual sobre Cosmetovigilancia registra un aumento del 30% de las notificaciones por efectos no deseados de productos cosméticos

Decision: Marketing authorisations granted in 2025

Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy

Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL

Medtronic to announce financial results for its fourth quarter and full fiscal year 2026

Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

The role of biomarkers: how new modalities are making precision medicine a reality

[IBENTO][IBENTO]The report for the PMDA-ATC Pharmacovigilance Seminar 2026 has been posted.

[SONOTA]Recent Publications by PMDA Staff updated

[KOKUSAI]The report for the APEC CoE workshop: PMDA-ATC Pharacovigilance Seminar 2026 has been posted.

[KOKUSAI]PMDA-ATC E-Learning Course contents have been released for FY2026

2026å¹´4月13日 ニュースリリース ã‚¢ãƒ«ãƒ„ãƒã‚¤ãƒžãƒ¼ç— é–¢é€£ã€è¡€æ¶²ä¸­ã®p-Tau217ã‚’æ¸¬å®šã™ã‚‹ç ”ç©¶ç”¨è©¦è–¬ã‚’ç™ºå£²

Sysmex Launches an Assay Kit for Identifying p-Tau217 in the Blood, a Biomarker Related to Alzheimer's Disease

Sysmex to Serve as Special Sponsor of Kobe Marathon 2026 – Supporting the Event Toward a Healthy, Prosperous Society and Vibrant Local Communities –

GSK plans five Phase 3 studies for gynecological cancer ADC from Hansoh

GSK presents positive data for B7-H4-targeted ADC in gynaecological cancers

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

More pharma dealmaking; FDA’s proposed budget; Takeda ends partnership; and more

Geliose Mobility, an IIT Delhi incubated startup, launches ‘HOPE’, an affordable electric scooter for last mile delivery and personal commute

Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 202

Predicting T Cell Recognition: New Insights from Large-Scale Activation Data

A study accepted to ML4H 2025 explores whether sequence-based models trained on large-scale T-cell a...

GAP Nail™ Endo-Exo Medullary System

Plan for remade ACIP panel adds focus on vaccine safety, matching Kennedy’s push

Bayer pharma executive predicts US-Europe price spreads will narrow

FDA rejects Replimune cancer therapy, saying company didn't resolve trial doubts

Register medical devices to place on the market

Decision: Advertising investigations: March 2026

GAMMAGARD LIQUID ERC Approved for Primary Immunodeficiency

Filing of Corporate Governance Report to the Tokyo Stock Exchange | Takeda Pharmaceuticals

Takeda Announces the Pricing Terms of the Previously Announced Cash Tender Offers for Certain Outstanding Notes | Takeda

Takeda Announces New Assignments of Directors

Statement on Inadvertent Abstract Disclosure for Oveporexton (TAK-861) by World Sleep Congress

Takeda Reports Third-Quarter FY2025 Results | Takeda Pharmaceuticals

Takeda Phase 3 Study Results in Pediatric Ulcerative Colitis

Rusfertides Phase 3 Trial for Polycythemia Vera at ASCO 2025

Takeda Presents Long-Term Data from ADVANCE-CIDP 3 Trial of HYQVIA

Takeda to Hold Third Quarter FY2022 Earnings Call on February 2

Takeda Receives Approval to Manufacture and Market Entyvio® Subcutaneous Injection in Japan for the Maintenance Treatment of Moderate to Severe Ulcerative Colitis

Notice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japan

ADZYNMA® Receives European Commission Approval as First Recombinant ADAMTS13 Therapy for cTTP

U.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older

Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor

Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary

FDA Accepts Takeda’s Entyvio BLA

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Nuevos proyecto de consulta para la opinión pública

Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics

Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.

Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress

Decision: Parallel import licences granted in 2026

Avacta CEO Christina Coughlin Named as One of In Vivo’s 2026 Rising Leaders

Medicines: Get integrated scientific advice from the MHRA and NICE

[ANZEN]MHLW Pharmaceuticals and Medical Devices Safety Information No.428 posted

[SHINSA]The information of New Drug Review with Electronic Data updated

Bausch Health's Dermatology Business, Ortho Dermatologics, Announces the Launch of Biafine®, an Iconic French Skincare Product, Through Convenient Online Ordering

Biotech Bulls & Breakthroughs podcast: The Future of Biomanufacturing with Michael Heltzen

Field Safety Notices: 6 to 10 April 2026

Repenser la santé depuis les territoires : le signal venu de Dunkerque

Decision: Triheptanoin in the treatment of long-chain fatty acid oxidation disorders (LC-FAOD)

NervGen Pharma to Participate in the H.C. Wainwright “HCW@Home” Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference

El Informe Anual sobre Cosmetovigilancia registra un aumento del 30% de las notificaciones por efectos no deseados de productos cosméticos

Decision: Marketing authorisations granted in 2025

Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy

Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL

Medtronic to announce financial results for its fourth quarter and full fiscal year 2026

Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

The role of biomarkers: how new modalities are making precision medicine a reality